United Therapeutics Quarterly Cash Flow Statement
NASDAQ: UTHRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
United Therapeutics free cash flow
In the quarter ended Jun 30, 2026, United Therapeutics generated $313.6 million of operating cash flow and spent $108.0 million on capital expenditures. That left free cash flow of $205.6 million, a free-cash-flow margin of 26.2% of revenue. Free cash flow was up 58.8% from the prior year's $129.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
United Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 333.00M | 274.90M | 364.30M | 338.70M | 309.50M | 322.20M | 301.30M | 309.10M | 278.10M | 306.60M | 217.10M | 267.60M |
| Net Income growth (YoY) | +7.59% | -14.68% | +20.91% | +9.58% | +11.29% | +5.09% | +38.78% | +15.51% | +7.29% | +27.27% | +64.35% | +11.83% |
| Depreciation & Amortization | 24.20M | 22.60M | 22.80M | 21.90M | 21.10M | 19.80M | 19.70M | 19.10M | 18.70M | 15.00M | 13.70M | 13.30M |
| Stock-Based Compensation | 43.40M | 33.90M | 39.00M | 39.10M | 37.80M | 31.80M | 27.00M | 41.70M | 49.70M | 25.60M | 16.60M | 21.10M |
| Change in Working Capital | -20.00M | -14.60M | -45.80M | 95.30M | -18.60M | -56.50M | 32.90M | -29.40M | 27.60M | -35.70M | -50.40M | 50.30M |
| Operating Cash Flow | 313.60M | 463.30M | 346.20M | 562.10M | 191.70M | 461.20M | 341.20M | 377.20M | 232.20M | 376.50M | 150.70M | 346.20M |
| Capital Expenditures | -108.00M | -100.80M | -172.90M | -210.50M | -62.20M | -74.90M | -86.70M | -76.50M | -45.10M | -38.20M | -78.70M | -65.70M |
| Investing Cash Flow | 87.50M | 743.70M | -227.60M | 140.90M | -299.90M | -164.70M | -123.20M | -114.90M | -80.00M | 735.30M | 42.10M | -313.40M |
| Share Repurchases | 0 | -1.50B | 0 | -1.00B | 0 | 0 | 0 | 0 | 0 | -1.00B | 0 | 0 |
| Financing Cash Flow | 122.40M | -1.48B | 98.40M | -956.00M | -198.60M | -93.80M | -74.70M | -64.10M | -48.00M | -1.07B | -92.80M | 7.60M |
| Net Change in Cash | 523.50M | -277.40M | 217.00M | -253.00M | -306.80M | 202.70M | 143.30M | 198.20M | 104.20M | 43.80M | 100.00M | 40.40M |
| Free Cash Flow | 205.60M | 362.50M | 173.30M | 351.60M | 129.50M | 386.30M | 254.50M | 300.70M | 187.10M | 338.30M | 72.00M | 280.50M |
This table shows 12 quarterly periods of United Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow UTHR's reporting calendar. What is a cash flow statement?